Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.

Farmoquimica S.A.46 enrolled

Overview

Primary: Evaluation of improved vaginal moisture in postmenopausal women. Secondary: the improvement of symptoms resulting from the dryness Rating (VHI), evaluation of the decrease in vaginal pH, assessment of Sexual Function Index female (FSFI), evaluation of adherence to study treatment by patient diary, assessing the acceptability of the product and subjective assessment of the patient as the itching and stinging / burning, beyond the safety assessment.

ENDPOINT: * Primary: Evaluation of improved vaginal moisture in post menopausal women through vaginal health index (VHI); * Secondaryevaluate the increase in fluid volume, vaginal elasticity and integrity of the epithelium by the VHI, evaluate the pH control, improvement of female sexual quality by applying the Sexual Function Index female (FSFI), evaluate through the patient's daily treatment adherence, evaluate the acceptability (welfare, run-off and satisfaction) of the product and the improvement of itching and stinging / burning through questionnaires and verify the tolerability and safety by identifying adverse events. STUDY DESING: Phase IV study, longitudinal, prospective, open label, non-comparative POPULATION: Forty-six (46) post menopausal women with vaginal dryness DRUG: Polimers and Sodium Lactate TREATMENT: Only treatment - two weekly applications (monday and thursday or tuesday and friday) for 12 weeks EVALUATION: The evaluation of the effectiveness will be held on all visits by medical clinical evaluation, evaluation of symptoms resulting from the dryness (VHI), pH evaluation (pH tape) and evaluation of female sexual quality (FSFI) and subjective evaluation as well as the compliance through the patient diary. The evaluation of the acceptability of the product will be the last visit by a questionnaire. The safety assessment will be carried out on all visits by identifying adverse events

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Vaginal Atrophy

Interventions

Hidra1DRUG

Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal. Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum. Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient.

Eligibility

Sex: FEMALEMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women over the age of 40 years. * in healthy postmenopausal women (not menstruating for more than one year). * Women with vaginal dryness (VHI score in item vaginal moisture between 1-3) * women with active sex lives of at least one sexual intercourse in the month * Women without a history of sensitivity to similar formulations. * understanding and signing an informed consent agreement. Exclusion Criteria: * Women in using other intravaginal gel moisturizer. * Women diagnosed with cancer. * Women with disease or condition that, in the opinion of the gynecologist, could affect the test results. * Women using hormone replacement therapy in the last 3 months. * Absence of history or visible evidence of chronic skin disease or regional infections. * Women with genital herpes, vaginal infections or urinary tract infection. * Pregnant women and nursing mothers. * Personal history of allergy and hypersensitivity to any product of feminine hygiene.

Outcomes

Primary Outcomes

Evaluation of improved vaginal moisture in post menopausal women by the Vaginal health index (VHI).

Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal

Time frame: 4 months

Scala: pH tape: It will be measured by its own value.

Time frame: 4 months

Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient.

Time frame: 4 months

Secondary Outcomes

Verify the tolerability and safety by identifying adverse events

Time frame: 4 months

Central Contacts

Fabiene Vale, Physician

CONTACT

55 31 91878133 fabienebcv@yahoo.com.br

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.